We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

73 hedge funds and large institutions have $251M invested in Karyopharm Therapeutics in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 20

52% more call options, than puts

Call options by funds: $1.24M | Put options by funds: $816K

0.34% less ownership

Funds ownership: 4.27% → 3.93% (-0.34%)

9% less funds holding

Funds holding: 80 → 73 (-7)

27% less capital invested

Capital invested by funds: $345M → $251M (-$93.3M)

50% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 12

Holders
73
Holders Change
-7
Holders Change %
-8.75%
% of All Funds
1.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
36
Reduced
20
Closed
12
Calls
$1.24M
Puts
$816K
Net Calls
+$427K
Net Calls Change
-$823K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.47M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.8M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$2.79M
4
CS
Candriam SCA
Luxembourg
+$2.62M
5
TCM
Tekla Capital Management
Massachusetts
+$1.49M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$4.76M
2
EI
EAM Investors
California
-$3.46M
3
Ameriprise
Ameriprise
Minnesota
-$1.13M
4
Russell Investments Group
Russell Investments Group
United Kingdom
-$962K
5
SCA
Secor Capital Advisors
New York
-$781K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$54.9M +$2.79M +18,870 +5%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$39.1M – – –
PAI
3
Palo Alto Investors
California
$31.4M +$603K +4,074 +2%
Franklin Resources
4
Franklin Resources
California
$28.1M -$453K -3,063 -1%
BlackRock
5
BlackRock
New York
$26.8M +$4.47M +30,183 +18%
Vanguard Group
6
Vanguard Group
Pennsylvania
$14.7M +$3.8M +25,644 +31%
TCM
7
Tekla Capital Management
Massachusetts
$6.85M +$1.49M +10,097 +25%
State Street
8
State Street
Massachusetts
$4.63M +$465K +3,142 +10%
CS
9
Candriam SCA
Luxembourg
$3.96M +$2.62M +17,733 +155%
TA
10
Teachers Advisors
New York
$3.9M +$106K +719 +3%
Northern Trust
11
Northern Trust
Illinois
$3.67M +$1.07M +7,225 +36%
SSA
12
Schonfeld Strategic Advisors
New York
$2.94M -$148K -1,000 -4%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$2.93M +$471K +3,180 +17%
IHM
14
Iguana Healthcare Management
New York
$2.71M +$247K +1,667 +9%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$2.36M +$904K +6,110 +54%
Millennium Management
16
Millennium Management
New York
$1.98M -$388K -2,623 -15%
BBA
17
Baker Bros. Advisors
New York
$1.96M – – –
Deutsche Bank
18
Deutsche Bank
Germany
$1.54M +$362K +2,447 +27%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$1.47M -$187K -1,262 -10%
MOACM
20
Mutual of America Capital Management
New York
$1.4M -$52.8K -357 -3%
Charles Schwab
21
Charles Schwab
California
$1.05M +$291K +1,968 +34%
TCIM
22
TIAA CREF Investment Management
New York
$936K +$339K +2,288 +50%
OPPM
23
Opus Point Partners Management
New York
$905K +$987K +6,667 New
USAA
24
United Services Automobile Association
Texas
$698K +$33.7K +228 +5%
RhumbLine Advisers
25
RhumbLine Advisers
Massachusetts
$677K +$59.4K +401 +9%
1
2 3 4

KPTI Hedge Fund Activity: Q2 2017 in Review

73 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2017, worth a combined $251M — down 27% from $345M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of KPTI and 6 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 36 added.

The largest buyer was BlackRock, adding an estimated $4.47M. The largest seller was JP Morgan Chase, cutting an estimated $4.76M.

  • 73 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2017, down from 80 in Q1 2017.
  • Funds reported $251M of Karyopharm Therapeutics stock for Q2 2017, down 27% quarter-over-quarter.
  • 6 funds opened new Karyopharm Therapeutics positions in Q2 2017 and 12 closed out, a net change of -6 holders.
  • The largest Karyopharm Therapeutics buyer in Q2 2017 was BlackRock, an estimated $4.47M added.
  • The largest Karyopharm Therapeutics seller in Q2 2017 was JP Morgan Chase, an estimated $4.76M sold.

Based on aggregated 13F filings for Q2 2017.